- Lord Resources (LRD) accelerates lithium exploration across its Horse Rocks project in Western Australia
- Infill auger sampling has begun, after LRD identified multiple geochemical anomalies in initial surface sampling work
- The first-pass exploration revealed elevated, near surface lithium, as well as mineral anomalies similar to Mineral Resources (MIN) nearby Mt Marion project
- Lord Resources says the results from the work completed so far was the catalyst to kicking off infill drilling in preparation for a larger drilling program in the new year
- Company shares were down 2.5 per cent, trading at 19.5 cents at 1:05 pm AEDT
Lord Resources (LRD) has accelerated lithium exploration across its Horse Rocks project in Western Australia.
The company recommenced low-impact, infill auger sampling after identifying multiple geochemical anomalies in initial surface sampling work.
The first-pass exploration revealed elevated, near-surface lithium, as well as mineral anomalies similar to Mineral Resources’ (MIN) nearby Mt Marion project.
Three priority one and four priority two anomalies have been mapped, with the most significant positioned in the centre of the project area, where the host greenstone units are folded.
This anomaly comprises elevated lithium, caesium, beryllium and a strong indication of fractionation with potassium and rubidium ratios.
Lord Resources’ Managing Director, Barnaby Egerton-Warburton, said the results from the mapping and sampling work completed so far provide an “excellent first step” for the project, and were a “catalyst” to “get back” and kick off infill work in preparation for a reverse circulation drilling program in the new year.
“The company firmly believes Horse Rocks has the potential to contain significant mineralisation and we will move quickly to identify targets and get drilling programs underway,” the MD said.
The current round of sampling is anticipated to take a week to complete with assays due in early 2023.
Meanwhile, 84 rock samples have been submitted for analysis with assays pending.
Company shares were down 2.5 per cent, trading at 19.5 cents at 1:05 pm AEDT.